Phase II Study of Fluconazole for Lymphocutaneous and Visceral Sporotrichosis (NCT00004938) | Clinical Trial Compass
CompletedPhase 2
Phase II Study of Fluconazole for Lymphocutaneous and Visceral Sporotrichosis
30 participantsStarted 1996-08
Plain-language summary
OBJECTIVE:
I. Evaluate the efficacy of fluconazole in patients with lymphocutaneous or visceral sporotrichosis.
Who can participate
Age range
12 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics-- Presumptive evidence of sporotrichosis Culture-proven sporotrichosis determined on study Relapsing disease following antifungal therapy eligible if culture positive for Sporothrix schenckii prior to entry No life-threatening disease No central nervous system sporotrichosis --Prior/Concurrent Therapy-- No concurrent drugs known to react with fluconazole No more than 3 days of systemic antifungals for current sporotrichosis episode --Patient Characteristics-- Hepatic: Liver function tests no greater than 5 times normal Other: No HIV infection No pregnant or nursing women
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this is a Phase II trial of fluconazole for sporotrichosis, what does that phase tell us about how much is already known about its safety and effectiveness, and how does that compare to more established treatments like itraconazole?
2My case involves either lymphocutaneous or visceral sporotrichosis — does my specific form of the disease match what this trial was studying, and does that affect whether the findings might be relevant to me?
3Since this trial is completed, have the results been published, and if so, what did they show about how well fluconazole worked compared to standard antifungal options?
4Fluconazole is already used for other fungal infections — does the fact that it was being studied specifically for sporotrichosis in this trial mean it isn't yet a standard choice for my condition, and should that concern me?
5Would it make more sense to start with a currently approved first-line treatment for my type of sporotrichosis before considering fluconazole, given that this trial was still in a Phase II testing stage?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Trial details
NCT IDNCT00004938
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)